The atypical antipsychotics risperidone,clozapine and olanzapine differ regarding their sedative potency in rats |
| |
Authors: | Ahnaou A Megens A A H P Drinkenburg W H I M |
| |
Affiliation: | Johnson & Johnson Pharmaceutical Research and Development, Division of Janssen Pharmaceutica N.V., Department of CNS Discovery Research, Beerse, Belgium. aahnaou@prdbe.jnj.com |
| |
Abstract: | The atypical antipsychotics risperidone, clozapine and olanzapine were studied for their ability to antagonise apomorphine-induced stereotypy and to affect electroencephalographic (EEG) activity in rats. The compounds antagonised apomorphine-induced stereotypy with ED(50)s of 0.15 mg/kg s.c. for risperidone, 0.42 mg/kg s.c. for olanzapine and 1.3 mg/kg s.c. for clozapine. At a dose close to that required for apomorphine antagonism (0.16 mg/kg s.c.), risperidone induced only minor changes in EEG power spectral activity. At a higher dosage (0.63 mg/kg s.c.) it increased the power density in the high frequency range (9.8-18.6 Hz), characteristic of a sedative-like effect. Olanzapine and clozapine caused a dose-dependent increase in power density in all frequency bands. These effects were already present at doses (0.04 and 0.16 mg/kg s.c., respectively) 10 times below those required for apomorphine antagonism. The effects increased dose-dependently and were pronounced at the doses required for apomorphine antagonism. These results in rats are in agreement with the clinical observation that risperidone has less propensity for inducing sedation at therapeutic dose levels than olanzapine and clozapine. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|